RelB and LTβ were highly expressed in cholangiocytes from patients with chronic liver diseases (hepatitis C and hepatitis B virus infections, alcoholic liver disease, non-alcoholic fatty liver disease, and autoimmune hepatitis) or cholangiopathies (primary biliary cirrhosis and primary sclerosing cholangitis) (36). The gene discussed is RELB; the disease is metabolic dysfunction-associated steatotic liver disease.